Şahin, Ahmet BilgehanMelek, HüseyinOcak, BirolOyucu Orhan, SibelErkan, BuketCaner, BurcuDeligönül, AdemÇubukcu, ErdemBayram, Ahmet SamiAkyıldız, Elif ÜlkerEvrensel, Türkkan2024-12-032024-12-032022-10-012049-9450https://doi.org/10.3892/mco.2022.2579https://www.spandidos-publications.com/10.3892/mco.2022.2579https://hdl.handle.net/11452/48811Chemotherapy is controversial in non-metastatic typical carcinoid (TC) tumors. Therefore, it was aimed to evaluate the impact of platin-based chemotherapy on the survival of patients with lung TC. The medical records of patients who underwent surgical resection for non-metastatic TC from 2002 to 2020 at our institution were retrospectively reviewed. Multivariate regression analysis was performed for chemotherapy and prognostic factors in disease-free survival (DFS) in 72 patients. The pathological stages of patients were as follows: 73.6% of the patients were in stage I, 15.3% in stage II and 11.1% in stage III. A total of 5 patients (6.9%) received platin-based chemotherapy and 6 patients (8.3%) had recurrences. The DFS rates at 12, 36 and 60 months were 98.5, 95.1 and 92.5%, respectively. Log-rank testing showed that patients who received chemotherapy and had stage III disease had shorter DFS (P=0.021 for chemotherapy and P<0.001 for stage). However, multivariate analysis revealed that the pathological stage was the only statistically significant factor affecting DFS (P=0.016). Platin-based chemotherapy did not improve DFS, and the eighth edition of TNM (tumor, nodes, metastases) staging did have prognostic value for patients with non-metastatic TC. Although resection has satisfying long-term outcomes, studies on new agents are needed to decrease the recurrence rate, particularly in patients with stage III disease.eninfo:eu-repo/semantics/openAccessSociety expert consensusAdjuvant chemotherapyNeuroendocrine tumorsLung-cancerGuidelinesManagementDiagnosisLung carcinoidTypical carcinoidChemotherapyStageSurvivalOncologyArticle00086450030000117410.3892/mco.2022.2579